CN117964773A - 多特异性结合蛋白及其改进 - Google Patents

Info

Publication number

CN117964773A

CN117964773A CN202311768455.3A CN202311768455A CN117964773A CN 117964773 A CN117964773 A CN 117964773A CN 202311768455 A CN202311768455 A CN 202311768455A CN 117964773 A CN117964773 A CN 117964773A

Authority

CN

China

Prior art keywords

seq

chain variable

amino acid

variable domain

acid sequence

Prior art date

2018-05-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000014914 Carrier Proteins Human genes 0.000 title abstract description 50
• 108091008324 binding proteins Proteins 0.000 title abstract description 50
• 230000006872 improvement Effects 0.000 title abstract description 7
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 174
• 239000012634 fragment Substances 0.000 claims abstract description 162
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 89
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 89
• 201000011510 cancer Diseases 0.000 claims abstract description 82
• 239000000427 antigen Substances 0.000 claims description 334
• 108091007433 antigens Proteins 0.000 claims description 334
• 102000036639 antigens Human genes 0.000 claims description 334
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 261
• 210000004027 cell Anatomy 0.000 claims description 159
• 239000000203 mixture Substances 0.000 claims description 53
• 210000000822 natural killer cell Anatomy 0.000 claims description 50
• 238000006467 substitution reaction Methods 0.000 claims description 43
• 238000009472 formulation Methods 0.000 claims description 41
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 38
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 32
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 32
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 27
• 150000001413 amino acids Chemical class 0.000 claims description 26
• 230000035772 mutation Effects 0.000 claims description 26
• 238000005734 heterodimerization reaction Methods 0.000 claims description 16
• 239000001608 potassium adipate Substances 0.000 claims description 16
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
• IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 claims description 11
• 239000003814 drug Substances 0.000 claims description 11
• 239000001601 sodium adipate Substances 0.000 claims description 10
• 201000001441 melanoma Diseases 0.000 claims description 9
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
• 206010042971 T-cell lymphoma Diseases 0.000 claims description 7
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 7
• 206010006187 Breast cancer Diseases 0.000 claims description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims description 6
• JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 210000004881 tumor cell Anatomy 0.000 claims description 6
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
• 150000007523 nucleic acids Chemical class 0.000 claims description 5
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
• 206010005003 Bladder cancer Diseases 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 4
• 206010027406 Mesothelioma Diseases 0.000 claims description 4
• 208000034578 Multiple myelomas Diseases 0.000 claims description 4
• 206010039491 Sarcoma Diseases 0.000 claims description 4
• 230000002708 enhancing effect Effects 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
• 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
• 206010029113 Neovascularisation Diseases 0.000 claims description 3
• 206010029260 Neuroblastoma Diseases 0.000 claims description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
• 206010057644 Testis cancer Diseases 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
• 201000004101 esophageal cancer Diseases 0.000 claims description 3
• 210000002744 extracellular matrix Anatomy 0.000 claims description 3
• 201000003444 follicular lymphoma Diseases 0.000 claims description 3
• 208000005017 glioblastoma Diseases 0.000 claims description 3
• 230000008595 infiltration Effects 0.000 claims description 3
• 238000001764 infiltration Methods 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• 239000011159 matrix material Substances 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 201000011549 stomach cancer Diseases 0.000 claims description 3
• 201000003120 testicular cancer Diseases 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
• 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
• 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 2
• 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
• 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 2
• 210000004899 c-terminal region Anatomy 0.000 claims description 2
• 230000030833 cell death Effects 0.000 claims description 2
• 230000008021 deposition Effects 0.000 claims description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
• 108020004707 nucleic acids Proteins 0.000 claims description 2
• 102000039446 nucleic acids Human genes 0.000 claims description 2
• 230000002611 ovarian Effects 0.000 claims description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
• 201000009377 thymus cancer Diseases 0.000 claims description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
• 239000000833 heterodimer Substances 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 15
• 238000002560 therapeutic procedure Methods 0.000 abstract 1
• 230000027455 binding Effects 0.000 description 368
• 108091008874 T cell receptors Proteins 0.000 description 161
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 160
• 108090000765 processed proteins & peptides Proteins 0.000 description 127
• 102000004196 processed proteins & peptides Human genes 0.000 description 82
• 229920001184 polypeptide Polymers 0.000 description 73
• 235000018102 proteins Nutrition 0.000 description 67
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 54
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 54
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 54
• 230000037396 body weight Effects 0.000 description 47
• 235000001014 amino acid Nutrition 0.000 description 38
• 201000009030 Carcinoma Diseases 0.000 description 32
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 27
• 108010075704 HLA-A Antigens Proteins 0.000 description 27
• 238000000034 method Methods 0.000 description 27
• 229940024606 amino acid Drugs 0.000 description 25
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 24
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 21
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
• 239000002609 medium Substances 0.000 description 18
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 17
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 17
• 230000001404 mediated effect Effects 0.000 description 17
• -1 such as Proteins 0.000 description 17
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 17
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 16
• 239000012669 liquid formulation Substances 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 239000003112 inhibitor Substances 0.000 description 15
• 239000000243 solution Substances 0.000 description 15
• 231100000135 cytotoxicity Toxicity 0.000 description 14
• 230000003013 cytotoxicity Effects 0.000 description 14
• 229960000575 trastuzumab Drugs 0.000 description 14
• 239000000872 buffer Substances 0.000 description 13
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 11
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 11
• 102100034256 Mucin-1 Human genes 0.000 description 11
• 230000009089 cytolysis Effects 0.000 description 11
• 229950011548 fadrozole Drugs 0.000 description 11
• 201000000050 myeloid neoplasm Diseases 0.000 description 11
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 10
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 10
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 9
• 239000004698 Polyethylene Substances 0.000 description 9
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 9
• 239000011230 binding agent Substances 0.000 description 9
• 238000001990 intravenous administration Methods 0.000 description 9
• 239000003755 preservative agent Substances 0.000 description 9
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 8
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
• 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 8
• 101710102605 MHC class I polypeptide-related sequence A Proteins 0.000 description 8
• 229930195725 Mannitol Natural products 0.000 description 8
• 238000002784 cytotoxicity assay Methods 0.000 description 8
• 231100000263 cytotoxicity test Toxicity 0.000 description 8
• 230000009615 deamination Effects 0.000 description 8
• 238000006481 deamination reaction Methods 0.000 description 8
• 239000000594 mannitol Substances 0.000 description 8
• 235000010355 mannitol Nutrition 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000008227 sterile water for injection Substances 0.000 description 8
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 7
• 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 7
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 7
• 102100029198 SLAM family member 7 Human genes 0.000 description 7
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 7
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 7
• 239000012931 lyophilized formulation Substances 0.000 description 7
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 7
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
• 229920000053 polysorbate 80 Polymers 0.000 description 7
• 101150013553 CD40 gene Proteins 0.000 description 6
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 6
• 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 6
• 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
• 239000008228 bacteriostatic water for injection Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 238000002648 combination therapy Methods 0.000 description 6
• 238000000684 flow cytometry Methods 0.000 description 6
• 229940022353 herceptin Drugs 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
• 239000000825 pharmaceutical preparation Substances 0.000 description 6
• 229920005862 polyol Polymers 0.000 description 6
• 150000003077 polyols Chemical class 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 230000009870 specific binding Effects 0.000 description 6
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 5
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 5
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 5
• 108010065524 CD52 Antigen Proteins 0.000 description 5
• 102100025221 CD70 antigen Human genes 0.000 description 5
• 102000001301 EGF receptor Human genes 0.000 description 5
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 5
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 5
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 5
• 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 5
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 5
• 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 5
• 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 5
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
• 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 5
• 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 5
• 108700020467 WT1 Proteins 0.000 description 5
• 101150084041 WT1 gene Proteins 0.000 description 5
• 102100022748 Wilms tumor protein Human genes 0.000 description 5
• 239000007853 buffer solution Substances 0.000 description 5
• 239000004067 bulking agent Substances 0.000 description 5
• 230000006037 cell lysis Effects 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 239000003599 detergent Substances 0.000 description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 230000002147 killing effect Effects 0.000 description 5
• 238000012423 maintenance Methods 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 230000000087 stabilizing effect Effects 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 4
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
• 229940124294 CD33 monoclonal antibody Drugs 0.000 description 4
• 102100035350 CUB domain-containing protein 1 Human genes 0.000 description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 102000017930 EDNRB Human genes 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 description 4
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 4
• 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 4
• 101000967299 Homo sapiens Endothelin receptor type B Proteins 0.000 description 4
• 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 4
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 4
• 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 4
• 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 4
• 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 4
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
• 102000003735 Mesothelin Human genes 0.000 description 4
• 108090000015 Mesothelin Proteins 0.000 description 4
• 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 4
• 108060006580 PRAME Proteins 0.000 description 4
• 102000036673 PRAME Human genes 0.000 description 4
• 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 4
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
• 102100037686 Protein SSX2 Human genes 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• 239000008365 aqueous carrier Substances 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
• 239000008366 buffered solution Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 229940127557 pharmaceutical product Drugs 0.000 description 4
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
• 229940068968 polysorbate 80 Drugs 0.000 description 4
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
• 230000000284 resting effect Effects 0.000 description 4
• 239000001509 sodium citrate Substances 0.000 description 4
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
• 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 3
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 3
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 102100034382 Plexin-A1 Human genes 0.000 description 3
• 101710100257 Plexin-A1 Proteins 0.000 description 3
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 3
• 108010002687 Survivin Proteins 0.000 description 3
• 101150117918 Tacstd2 gene Proteins 0.000 description 3
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 3
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
• 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 3
• 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 208000009956 adenocarcinoma Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 150000001720 carbohydrates Chemical group 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 230000007402 cytotoxic response Effects 0.000 description 3
• 150000002016 disaccharides Chemical class 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 238000004108 freeze drying Methods 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 208000000649 small cell carcinoma Diseases 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 229960002317 succinimide Drugs 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
• 102100022464 5'-nucleotidase Human genes 0.000 description 2
• 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 2
• 102100022749 Aminopeptidase N Human genes 0.000 description 2
• 102100022992 Anoctamin-1 Human genes 0.000 description 2
• 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 description 2
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
• 108010074708 B7-H1 Antigen Proteins 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
• 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
• 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 2
• 108700012439 CA9 Proteins 0.000 description 2
• 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
• 108010017009 CD11b Antigen Proteins 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 102100027221 CD81 antigen Human genes 0.000 description 2
• 102100029400 CMRF35-like molecule 7 Human genes 0.000 description 2
• 101150031358 COLEC10 gene Proteins 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
• 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
• 108050007957 Cadherin Proteins 0.000 description 2
• 102000000905 Cadherin Human genes 0.000 description 2
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
• 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
• 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 2
• 208000005243 Chondrosarcoma Diseases 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
• 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 102100036466 Delta-like protein 3 Human genes 0.000 description 2
• 102100024364 Disintegrin and metalloproteinase domain-containing protein 8 Human genes 0.000 description 2
• 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 description 2
• 102000006539 ELAV-Like Protein 4 Human genes 0.000 description 2
• 108010008802 ELAV-Like Protein 4 Proteins 0.000 description 2
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 2
• 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 2
• 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 2
• SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 2
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 102000056372 ErbB-3 Receptor Human genes 0.000 description 2
• 229910052693 Europium Inorganic materials 0.000 description 2
• 102000010451 Folate receptor alpha Human genes 0.000 description 2
• 108050001931 Folate receptor alpha Proteins 0.000 description 2
• 102100039717 G antigen 1 Human genes 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• 102100032530 Glypican-3 Human genes 0.000 description 2
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2
• 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 2
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
• 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
• 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 2
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
• 101000757261 Homo sapiens Anoctamin-1 Proteins 0.000 description 2
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
• 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
• 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 description 2
• 101000990007 Homo sapiens CMRF35-like molecule 7 Proteins 0.000 description 2
• 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
• 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 2
• 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 2
• 101000832767 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 8 Proteins 0.000 description 2
• 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 description 2
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 2
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
• 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 2
• 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 2
• 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
• 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
• 101001039157 Homo sapiens Leucine-rich repeat-containing protein 25 Proteins 0.000 description 2
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
• 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 description 2
• 101000984200 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 3 Proteins 0.000 description 2
• 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 2
• 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 2
• 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 2
• 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 2
• 101000984185 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 5 Proteins 0.000 description 2
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
• 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 2
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 2
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
• 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 2
• 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 2
• 101000709256 Homo sapiens Signal-regulatory protein beta-1 Proteins 0.000 description 2
• 101000709188 Homo sapiens Signal-regulatory protein beta-1 isoform 3 Proteins 0.000 description 2
• 101000753178 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-3 Proteins 0.000 description 2
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
• 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 2
• 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
• 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 2
• 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 2
• 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 2
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102100022338 Integrin alpha-M Human genes 0.000 description 2
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
• 102000002698 KIR Receptors Human genes 0.000 description 2
• 108010043610 KIR Receptors Proteins 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 102100040695 Leucine-rich repeat-containing protein 25 Human genes 0.000 description 2
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
• 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 description 2
• 102100025556 Leukocyte immunoglobulin-like receptor subfamily A member 3 Human genes 0.000 description 2
• 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 description 2
• 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 2
• 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 2
• 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 2
• 102100025577 Leukocyte immunoglobulin-like receptor subfamily B member 5 Human genes 0.000 description 2
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
• 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 2
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 2
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
• 208000003445 Mouth Neoplasms Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 2
• 101150084398 PTAFR gene Proteins 0.000 description 2
• 108030001694 Pappalysin-1 Proteins 0.000 description 2
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
• 108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 108091007561 SLC44A4 Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 2
• 102100032770 Signal-regulatory protein beta-1 isoform 3 Human genes 0.000 description 2
• 102100021952 Sodium/potassium-transporting ATPase subunit alpha-3 Human genes 0.000 description 2
• 101800001271 Surface protein Proteins 0.000 description 2
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
• 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
• 102000003425 Tyrosinase Human genes 0.000 description 2
• 108060008724 Tyrosinase Proteins 0.000 description 2
• 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
• 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 2
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 239000013011 aqueous formulation Substances 0.000 description 2
• 239000008135 aqueous vehicle Substances 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• 238000002619 cancer immunotherapy Methods 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000007979 citrate buffer Substances 0.000 description 2
• 229960004106 citric acid Drugs 0.000 description 2
• 229960002303 citric acid monohydrate Drugs 0.000 description 2
• 229960002436 cladribine Drugs 0.000 description 2
• 238000003501 co-culture Methods 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 229940127276 delta-like ligand 3 Drugs 0.000 description 2
• 238000000432 density-gradient centrifugation Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 229940126534 drug product Drugs 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 229920001971 elastomer Polymers 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 229950011487 enocitabine Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
• 238000012494 forced degradation Methods 0.000 description 2
• 229960004421 formestane Drugs 0.000 description 2
• OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 229960003881 letrozole Drugs 0.000 description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 229960001614 levamisole Drugs 0.000 description 2
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 229960005485 mitobronitol Drugs 0.000 description 2
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 2
• 229950010913 mitolactol Drugs 0.000 description 2
• 229950006780 n-acetylglucosamine Drugs 0.000 description 2
• 229920002113 octoxynol Polymers 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 102000030769 platelet activating factor receptor Human genes 0.000 description 2
• 108050009312 plexin Proteins 0.000 description 2
• 102000002022 plexin Human genes 0.000 description 2
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 229950010131 puromycin Drugs 0.000 description 2
• 229960004432 raltitrexed Drugs 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 108091005418 scavenger receptor class E Proteins 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
• 229960001674 tegafur Drugs 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 229960001278 teniposide Drugs 0.000 description 2
• 238000011287 therapeutic dose Methods 0.000 description 2
• 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
• DEEULBIVHZVMHX-UHFFFAOYSA-N 1-nitroacridine Chemical compound C1=CC=C2C=C3C([N+](=O)[O-])=CC=CC3=NC2=C1 DEEULBIVHZVMHX-UHFFFAOYSA-N 0.000 description 1
• ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
• 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000004860 Blast Crisis Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 102100027207 CD27 antigen Human genes 0.000 description 1
• 102100038078 CD276 antigen Human genes 0.000 description 1
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
• 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 241000282832 Camelidae Species 0.000 description 1
• SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
• 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
• 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
• 108010049207 Death Domain Receptors Proteins 0.000 description 1
• 102000009058 Death Domain Receptors Human genes 0.000 description 1
• 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 1
• 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 239000005894 Emamectin Substances 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
• OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 208000004057 Focal Nodular Hyperplasia Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 206010019629 Hepatic adenoma Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
• 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 1
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
• 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 1
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 101100101727 Homo sapiens RAET1L gene Proteins 0.000 description 1
• 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
• 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
• 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
• 102220580970 Induced myeloid leukemia cell differentiation protein Mcl-1_I50T_mutation Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 208000036241 Liver adenomatosis Diseases 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 229940124787 MELK inhibitor Drugs 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000003351 Melanosis Diseases 0.000 description 1
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
• IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000002231 Muscle Neoplasms Diseases 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• 102100035486 Nectin-4 Human genes 0.000 description 1
• 101710043865 Nectin-4 Proteins 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 1
• 239000012661 PARP inhibitor Substances 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010061336 Pelvic neoplasm Diseases 0.000 description 1
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
• 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
• 229940079156 Proteasome inhibitor Drugs 0.000 description 1
• 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
• 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
• 206010051807 Pseudosarcoma Diseases 0.000 description 1
• 201000008183 Pulmonary blastoma Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
• 229920002305 Schizophyllan Polymers 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
• 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010054184 Small intestine carcinoma Diseases 0.000 description 1
• OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010078233 Thymalfasin Proteins 0.000 description 1
• 208000033781 Thyroid carcinoma Diseases 0.000 description 1
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
• 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
• 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
• 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
• 102100040013 UL16-binding protein 6 Human genes 0.000 description 1
• 101150013568 US16 gene Proteins 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 208000009311 VIPoma Diseases 0.000 description 1
• 201000003761 Vaginal carcinoma Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
• 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
• WVTGEXAIVZDLCR-UHFFFAOYSA-N Vindoline Natural products CC1C2CN3CCCC14CCC5Nc6ccccc6C25C34 WVTGEXAIVZDLCR-UHFFFAOYSA-N 0.000 description 1
• 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 201000001256 adenosarcoma Diseases 0.000 description 1
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 239000004178 amaranth Substances 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 208000002896 anal canal carcinoma Diseases 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
• 208000029336 bartholin gland carcinoma Diseases 0.000 description 1
• 230000033590 base-excision repair Effects 0.000 description 1
• 229960002707 bendamustine Drugs 0.000 description 1
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 210000003445 biliary tract Anatomy 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960002115 carboquone Drugs 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 208000025106 carcinoma of duodenum Diseases 0.000 description 1
• 208000025085 carcinoma of parotid gland Diseases 0.000 description 1
• 208000025188 carcinoma of pharynx Diseases 0.000 description 1
• 208000022033 carcinoma of urethra Diseases 0.000 description 1
• GKWYINOZGDHWRA-UHFFFAOYSA-N catharanthine Natural products C1C(CC)(O)CC(CC2C(=O)OC)CN1CCC1=C2NC2=CC=CC=C12 GKWYINOZGDHWRA-UHFFFAOYSA-N 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
• 229960003230 cetrorelix Drugs 0.000 description 1
• 108700008462 cetrorelix Proteins 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 210000003161 choroid Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 108091008034 costimulatory receptors Proteins 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000006240 deamidation Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 108010017271 denileukin diftitox Proteins 0.000 description 1
• 229960002923 denileukin diftitox Drugs 0.000 description 1
• 238000011118 depth filtration Methods 0.000 description 1
• 208000018554 digestive system carcinoma Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 239000000806 elastomer Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
• 201000006828 endometrial hyperplasia Diseases 0.000 description 1
• 201000000330 endometrial stromal sarcoma Diseases 0.000 description 1
• 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
• 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 229950002973 epitiostanol Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 210000000285 follicular dendritic cell Anatomy 0.000 description 1
• 238000012495 forced degradation study Methods 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 102000056982 human CD33 Human genes 0.000 description 1
• 102000051957 human ERBB2 Human genes 0.000 description 1
• 102000044042 human KLRK1 Human genes 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
• 229950008097 improsulfan Drugs 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 201000011061 large intestine cancer Diseases 0.000 description 1
• 201000005264 laryngeal carcinoma Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229960003587 lisuride Drugs 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 229940124302 mTOR inhibitor Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 201000005831 male reproductive organ cancer Diseases 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 229950009246 mepitiostane Drugs 0.000 description 1
• 208000011645 metastatic carcinoma Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000012434 mixed-mode chromatography Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 201000002077 muscle cancer Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 210000001167 myeloblast Anatomy 0.000 description 1
• 229950007221 nedaplatin Drugs 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 201000011682 nervous system cancer Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
• 229950008607 nitracrine Drugs 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 231100000065 noncytotoxic Toxicity 0.000 description 1
• 230000002020 noncytotoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
• 229960005244 oxymetholone Drugs 0.000 description 1
• ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
• 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
• 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 208000030940 penile carcinoma Diseases 0.000 description 1
• 201000008174 penis carcinoma Diseases 0.000 description 1
• 229930192851 perforin Natural products 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000002974 pharmacogenomic effect Effects 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229940044519 poloxamer 188 Drugs 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• 229960004694 prednimustine Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 239000003207 proteasome inhibitor Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 208000020615 rectal carcinoma Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• 208000037968 sinus cancer Diseases 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 230000008410 smoothened signaling pathway Effects 0.000 description 1
• 229950010372 sobuzoxane Drugs 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229960002668 sodium chloride Drugs 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 229940074404 sodium succinate Drugs 0.000 description 1
• ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
• 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
• 229960004231 thymalfasin Drugs 0.000 description 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
• 230000009258 tissue cross reactivity Effects 0.000 description 1
• 208000025358 tongue carcinoma Diseases 0.000 description 1
• 239000012929 tonicity agent Substances 0.000 description 1
• 239000008181 tonicity modifier Substances 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
• 201000007433 ureter carcinoma Diseases 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• 230000001720 vestibular Effects 0.000 description 1
• CXBGOBGJHGGWIE-IYJDUVQVSA-N vindoline Chemical compound CN([C@H]1[C@](O)([C@@H]2OC(C)=O)C(=O)OC)C3=CC(OC)=CC=C3[C@]11CCN3CC=C[C@]2(CC)[C@@H]13 CXBGOBGJHGGWIE-IYJDUVQVSA-N 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1